1. Home
  2. ADVM vs BRFH Comparison

ADVM vs BRFH Comparison

Compare ADVM & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • BRFH
  • Stock Information
  • Founded
  • ADVM 2006
  • BRFH 2005
  • Country
  • ADVM United States
  • BRFH United States
  • Employees
  • ADVM N/A
  • BRFH N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • BRFH Packaged Foods
  • Sector
  • ADVM Health Care
  • BRFH Consumer Staples
  • Exchange
  • ADVM Nasdaq
  • BRFH Nasdaq
  • Market Cap
  • ADVM 47.4M
  • BRFH 47.3M
  • IPO Year
  • ADVM 2014
  • BRFH N/A
  • Fundamental
  • Price
  • ADVM $2.25
  • BRFH $2.63
  • Analyst Decision
  • ADVM Strong Buy
  • BRFH Strong Buy
  • Analyst Count
  • ADVM 5
  • BRFH 1
  • Target Price
  • ADVM $26.40
  • BRFH $4.50
  • AVG Volume (30 Days)
  • ADVM 186.4K
  • BRFH 5.6K
  • Earning Date
  • ADVM 08-11-2025
  • BRFH 08-13-2025
  • Dividend Yield
  • ADVM N/A
  • BRFH N/A
  • EPS Growth
  • ADVM N/A
  • BRFH N/A
  • EPS
  • ADVM N/A
  • BRFH N/A
  • Revenue
  • ADVM $1,000,000.00
  • BRFH $10,818,000.00
  • Revenue This Year
  • ADVM N/A
  • BRFH $42.31
  • Revenue Next Year
  • ADVM $18.82
  • BRFH $40.92
  • P/E Ratio
  • ADVM N/A
  • BRFH N/A
  • Revenue Growth
  • ADVM N/A
  • BRFH 22.03
  • 52 Week Low
  • ADVM $1.78
  • BRFH $1.81
  • 52 Week High
  • ADVM $10.14
  • BRFH $4.61
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 40.11
  • BRFH 46.20
  • Support Level
  • ADVM $2.21
  • BRFH $2.79
  • Resistance Level
  • ADVM $3.10
  • BRFH $3.01
  • Average True Range (ATR)
  • ADVM 0.22
  • BRFH 0.22
  • MACD
  • ADVM -0.00
  • BRFH -0.00
  • Stochastic Oscillator
  • ADVM 4.49
  • BRFH 35.53

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About BRFH Barfresh Food Group Inc.

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

Share on Social Networks: